{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:55:23Z","timestamp":1788479723869,"version":"build-2803163510"},"reference-count":86,"publisher":"The Endocrine Society","issue":"2","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>As consensus regarding outcome sets for prolactinoma treatment evaluation is lacking, this study evaluated outcome parameters reported in the literature, and objective, clinically relevant outcome sets were proposed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review of studies up to February 2, 2024. Reported biochemical and radiological parameters; clinician-reported findings; patient-reported outcomes (PROs); and definitions of disease remission, control, and recurrence were extracted and placed into a clinical context. Subsequently, objective and clinically relevant definitions of clinical outcomes were proposed based on the findings, with comprehensive outcome sets to evaluate treatment success.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One hundred thirty-seven articles were included. Albeit ill-defined or subjective, 23 unique prolactin parameters and 73 unique radiological parameters were reported. Seventy articles included clinician-reported findings, and none reported PROs. Ultimately, 27 unique definitions of remission, 3 unique definitions of disease control, and 20 unique definitions of recurrence were reported. We propose 2 separate definitions for biochemical and clinical remission\/recurrence\u2014either evaluating prolactin levels only or including symptomology, gonadal function, and radiology. Integrated outcome quadrants were illustrated to objectively categorize treatment success by combining achievement of treatment goals with the occurrence of adverse effects. A 3-tier outcome set based on the Value-Based Healthcare principles is provided.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Heterogeneity in reported outcome parameters using varying definitions hampers the comparison of prolactinoma treatment outcomes. This study proposes objective, easily applicable, and clinically relevant definitions of clinical outcomes and offers a comprehensive outcome set. These parameters enable comparison of outcomes across treatment modalities and medical centers to gain insight into this rare disease and improve prolactinoma care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgaf540","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:54:07Z","timestamp":1758974047000},"page":"303-315","source":"Crossref","is-referenced-by-count":3,"title":["How to Define Success in Prolactinoma Treatment\u2014A Systematic Review and Theoretical Framework"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5658-0679","authenticated-orcid":false,"given":"Victoria R","family":"van Trigt","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, and Center for Endocrine Tumors Leiden, Leiden University Medical Center , Leiden 2333 ZA ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7137-1074","authenticated-orcid":false,"given":"Kevin A","family":"Huynh","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, and Center for Endocrine Tumors Leiden, Leiden University Medical Center , Leiden 2333 ZA ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3549-0184","authenticated-orcid":false,"given":"Leontine E H","family":"Bakker","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, and Center for Endocrine Tumors Leiden, Leiden University Medical Center , Leiden 2333 ZA ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4956-4037","authenticated-orcid":false,"given":"Iris C M","family":"Pelsma","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, and Center for Endocrine Tumors Leiden, Leiden University Medical Center , Leiden 2333 ZA ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1077-8273","authenticated-orcid":false,"given":"Ingrid M","family":"Zandbergen","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Leiden University Medical Center, University Neurosurgical Center Holland , Leiden 2333 ZA ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2400-2070","authenticated-orcid":false,"given":"Amir H","family":"Zamanipoor Najafabadi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Leiden University Medical Center , Leiden 2333 ZA ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9739-7515","authenticated-orcid":false,"given":"Marco J T","family":"Verstegen","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Leiden University Medical Center, University Neurosurgical Center Holland , Leiden 2333 ZA ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5208-921X","authenticated-orcid":false,"given":"Wouter R","family":"van Furth","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Leiden University Medical Center, University Neurosurgical Center Holland , Leiden 2333 ZA ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5817-3594","authenticated-orcid":false,"given":"Nienke R","family":"Biermasz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, and Center for Endocrine Tumors Leiden, Leiden University Medical Center , Leiden 2333 ZA ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"issue":"1","key":"2026012101525801600_dgaf540-B1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1210\/jc.2009-1238","article-title":"Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis","volume":"95","author":"Dekkers","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026012101525801600_dgaf540-B2","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1210\/clinem\/dgz144","article-title":"Surgery as a viable alternative first-line treatment for prolactinoma patients. A systematic review and meta-analysis","volume":"105","author":"Zamanipoor Najafabadi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026012101525801600_dgaf540-B3","doi-asserted-by":"crossref","first-page":"e1833","DOI":"10.1210\/clinem\/dgae652","article-title":"The changing treatment paradigm in prolactinoma\u2014a prospective series of 100 consecutive neurosurgical cases","volume":"110","author":"van Trigt","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026012101525801600_dgaf540-B4","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas","volume":"27","author":"Gillam","year":"2006","journal-title":"Endocr Rev"},{"key":"2026012101525801600_dgaf540-B5","doi-asserted-by":"crossref","unstructured":"van Trigt VR, Huynh KA, Bakker LEH, et al \u00a0Supplementary Tables and Figures belonging to: \u201cHow to Define Success in Prolactinoma Treatment-A Systematic Review and Theoretical Framework\u201d. Figshare. Journal contribution. 2025. 10.6084\/m9.figshare.30307465","DOI":"10.1210\/clinem\/dgaf540"},{"issue":"6","key":"2026012101525801600_dgaf540-B6","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s11154-024-09927-4","article-title":"Reference intervals for serum prolactin concentrations: analytical and clinical considerations","volume":"25","author":"Coleman","year":"2024","journal-title":"Rev Endocr Metab Disord"},{"issue":"6","key":"2026012101525801600_dgaf540-B7","doi-asserted-by":"crossref","first-page":"bvae069","DOI":"10.1210\/jendso\/bvae069","article-title":"Clinical impact of new reference intervals for the Roche prolactin II immunoassay","volume":"8","author":"Earll","year":"2024","journal-title":"J Endocr Soc"},{"issue":"12","key":"2026012101525801600_dgaf540-B8","doi-asserted-by":"crossref","first-page":"e240432","DOI":"10.1530\/EC-24-0432","article-title":"Confusion in the interpretation of prolactin levels caused by inappropriately low reference intervals","volume":"13","author":"Sabogal Pi\u00f1eros","year":"2024","journal-title":"Endocr Connect"},{"issue":"9234","key":"2026012101525801600_dgaf540-B9","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S0140-6736(00)02697-0","article-title":"Galactorrhoea and hyperprolactinaemia associated with protease-inhibitors","volume":"356","author":"Hutchinson","year":"2000","journal-title":"Lancet"},{"issue":"1","key":"2026012101525801600_dgaf540-B10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11102-019-01024-z","article-title":"Biochemical diagnosis in prolactinomas: some caveats","volume":"23","author":"Petersenn","year":"2020","journal-title":"Pituitary"},{"issue":"12","key":"2026012101525801600_dgaf540-B11","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society International Consensus Statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"2026012101525801600_dgaf540-B12","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s11102-022-01246-8","article-title":"Prolactin immunoassay: does the high-dose hook effect still exist?","volume":"25","author":"Raverot","year":"2022","journal-title":"Pituitary"},{"issue":"12","key":"2026012101525801600_dgaf540-B13","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s40618-016-0483-z","article-title":"Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas","volume":"39","author":"Sala","year":"2016","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"2026012101525801600_dgaf540-B14","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/cen.12204","article-title":"Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels","volume":"79(6)","author":"Ciresi","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2026012101525801600_dgaf540-B15","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1210\/jc.2003-030852","article-title":"Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence","volume":"89","author":"De Rosa","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026012101525801600_dgaf540-B16","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1210\/jcem.86.11.8054","article-title":"Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy","volume":"86","author":"Di Sarno","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026012101525801600_dgaf540-B17","first-page":"199","article-title":"Ki-67 and clinical correlations in patients with resistant prolactinomas","volume":"50","author":"Lu","year":"2020","journal-title":"Ann Clin Lab Sci"},{"issue":"1","key":"2026012101525801600_dgaf540-B18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12020-019-02076-8","article-title":"Surgical management considerations in cystic prolactinomas-a single center case series","volume":"67","author":"Nevzati","year":"2020","journal-title":"Endocrine"},{"issue":"2","key":"2026012101525801600_dgaf540-B19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.14791\/btrt.2013.1.2.71","article-title":"Bromocriptine therapy for the treatment of invasive prolactinoma: the single institute experience","volume":"1","author":"Cho","year":"2013","journal-title":"Brain Tumor Res Treat"},{"issue":"3","key":"2026012101525801600_dgaf540-B20","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s11102-022-01221-3","article-title":"The role of endoscopic endonasal surgery in the management of prolactinomas based on their invasiveness into the cavernous sinus","volume":"25","author":"Abou-Al-Shaar","year":"2022","journal-title":"Pituitary"},{"issue":"6","key":"2026012101525801600_dgaf540-B21","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.3171\/jns.1999.90.6.1037","article-title":"An ultrarapid prognostic index in microprolactinoma surgery","volume":"90","author":"Guieu","year":"1999","journal-title":"J Neurosurg"},{"key":"2026012101525801600_dgaf540-B22","doi-asserted-by":"crossref","first-page":"e1166","DOI":"10.1016\/j.wneu.2023.04.089","article-title":"The combination of dopamine agonist treatment and surgery may be the best option in challenging prolactinoma cases: a single-centre experience","volume":"175","author":"Demir","year":"2023","journal-title":"World Neurosurg"},{"key":"2026012101525801600_dgaf540-B23","doi-asserted-by":"crossref","first-page":"1179551420926181","DOI":"10.1177\/1179551420926181","article-title":"Clinical features, therapeutic trends, and outcome of giant prolactinomas: a single-center experience over a 12-year period","volume":"13","author":"Almalki","year":"2020","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"issue":"1","key":"2026012101525801600_dgaf540-B24","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s10143-023-02033-0","article-title":"Surgery as first-line treatment for prolactinoma? Discussion of the literature and results of a consecutive series of surgically treated patients","volume":"46","author":"Ottenhausen","year":"2023","journal-title":"Neurosurg Rev"},{"issue":"45","key":"2026012101525801600_dgaf540-B25","doi-asserted-by":"crossref","first-page":"e13198","DOI":"10.1097\/MD.0000000000013198","article-title":"Retrospective analysis of 52 patients with prolactinomas following endoscopic endonasal transsphenoidal surgery","volume":"97","author":"Han","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"2026012101525801600_dgaf540-B26","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s42000-021-00307-0","article-title":"Comparison of the effects of medical and surgical treatments in giant prolactinoma: a single-center experience","volume":"20","author":"Cander","year":"2021","journal-title":"Hormones (Athens)"},{"issue":"8","key":"2026012101525801600_dgaf540-B27","doi-asserted-by":"crossref","first-page":"102919","DOI":"10.1016\/j.arcmed.2023.102919","article-title":"Efficacy and safety of endoscopic transsphenoidal resection for prolactinoma: a retrospective multicenter case-series","volume":"54","author":"Zandbergen","year":"2023","journal-title":"Arch Med Res"},{"issue":"5","key":"2026012101525801600_dgaf540-B28","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s11102-023-01346-z","article-title":"Care trajectories of surgically treated patients with a prolactinoma: why did they opt for surgery?","volume":"26","author":"van Trigt","year":"2023","journal-title":"Pituitary"},{"issue":"6","key":"2026012101525801600_dgaf540-B29","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.beem.2011.05.011","article-title":"Prolactinoma in pregnancy","volume":"25","author":"Molitch","year":"2011","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"6","key":"2026012101525801600_dgaf540-B30","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1590\/2359-3997000000230","article-title":"Interactions between prolactin and kisspeptin to control reproduction","volume":"60","author":"Donato","year":"2016","journal-title":"Arch Endocrinol Metab"},{"issue":"5","key":"2026012101525801600_dgaf540-B31","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/cen.15097","article-title":"Society for endocrinology guideline for understanding, diagnosing and treating female hypogonadism","volume":"101","author":"Jayasena","year":"2024","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2026012101525801600_dgaf540-B32","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11102-008-0109-3","article-title":"Female hypogonadism: evaluation of the hypothalamic-pituitary-ovarian axis","volume":"11","author":"Rothman","year":"2008","journal-title":"Pituitary"},{"issue":"3","key":"2026012101525801600_dgaf540-B33","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3803\/EnM.2020.760","article-title":"Current national and international guidelines for the management of male hypogonadism: helping clinicians to navigate variation in diagnostic criteria and treatment recommendations","volume":"35","author":"Al-Sharefi","year":"2020","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"11","key":"2026012101525801600_dgaf540-B34","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1210\/jc.2016-2118","article-title":"Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline","volume":"101","author":"Fleseriu","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026012101525801600_dgaf540-B35","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2265.2012.04486.x","article-title":"Abrupt decrease in serum testosterone levels after an oral glucose load in men: implications for screening for hypogonadism","volume":"78","author":"Caronia","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2026012101525801600_dgaf540-B36","doi-asserted-by":"crossref","first-page":"101683","DOI":"10.1016\/j.beem.2022.101683","article-title":"Accurate measurement of total and free testosterone levels for the diagnosis of androgen disorders","volume":"36","author":"Guzelce","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"Pt 1","key":"2026012101525801600_dgaf540-B37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1258\/000456306775141803","article-title":"Analytical and physiological factors affecting the interpretation of serum testosterone concentration in men","volume":"43","author":"Diver","year":"2006","journal-title":"Ann Clin Biochem"},{"issue":"9924","key":"2026012101525801600_dgaf540-B38","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S0140-6736(13)61126-5","article-title":"Male hypogonadism","volume":"383","author":"Basaria","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"2026012101525801600_dgaf540-B39","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s12020-022-03238-x","article-title":"Metabolic effects of dopamine-agonists treatment among patients with prolactinomas","volume":"79","author":"Kabootari","year":"2023","journal-title":"Endocrine"},{"issue":"2","key":"2026012101525801600_dgaf540-B40","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026012101525801600_dgaf540-B41","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s12020-017-1444-9","article-title":"Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis","volume":"59","author":"Xia","year":"2018","journal-title":"Endocrine"},{"issue":"5","key":"2026012101525801600_dgaf540-B42","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s007010200064","article-title":"Magnetic resonance imaging after transsphenoidal surgery of clinically non-functional pituitary macroadenomas and its impact on detecting residual adenoma","volume":"144","author":"Kremer","year":"2002","journal-title":"Acta Neurochir (Wien)"},{"issue":"4","key":"2026012101525801600_dgaf540-B43","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1179\/1743132814Y.0000000457","article-title":"Serial 3 T magnetic resonance imaging during cabergoline treatment of macroprolactinomas","volume":"37","author":"Kurosaki","year":"2015","journal-title":"Neurol Res"},{"issue":"2","key":"2026012101525801600_dgaf540-B44","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11102-005-5111-4","article-title":"Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men","volume":"8","author":"Chattopadhyay","year":"2005","journal-title":"Pituitary"},{"issue":"2","key":"2026012101525801600_dgaf540-B45","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1515\/hmbci-2020-0077","article-title":"Outcomes of surgical and\/or medical treatment in patients with prolactinomas during long-term follow-up: a retrospective single-centre study","volume":"42","author":"Akkus","year":"2020","journal-title":"Horm Mol Biol Clin Investig"},{"issue":"1","key":"2026012101525801600_dgaf540-B46","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11102-011-0303-6","article-title":"Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience","volume":"15","author":"Anagnostis","year":"2012","journal-title":"Pituitary"},{"issue":"1","key":"2026012101525801600_dgaf540-B47","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ando.2021.11.005","article-title":"Optimal testosterone level to improve symptoms of hypogonadism without causing dopa-testotoxicosis in male macroprolactinoma","volume":"83","author":"Telci Caklili","year":"2022","journal-title":"Ann Endocrinol (Paris)"},{"issue":"6","key":"2026012101525801600_dgaf540-B48","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s11102-021-01168-x","article-title":"Surgery is a safe, effective first-line treatment modality for noninvasive prolactinomas","volume":"24","author":"Park","year":"2021","journal-title":"Pituitary"},{"issue":"13","key":"2026012101525801600_dgaf540-B49","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.3390\/cancers13133252","article-title":"Reappraising the role of trans-sphenoidal surgery in prolactin-secreting pituitary tumors","volume":"13","author":"Mattogno","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"8","key":"2026012101525801600_dgaf540-B50","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3349\/ymj.2022.0406","article-title":"Surgical treatment of prolactinomas: potential role as a first-line treatment modality","volume":"64","author":"Kim","year":"2023","journal-title":"Yonsei Med J"},{"issue":"2","key":"2026012101525801600_dgaf540-B51","doi-asserted-by":"crossref","first-page":"e5833","DOI":"10.1097\/MD.0000000000005833","article-title":"Surgical treatment for male prolactinoma: a retrospective study of 184 cases","volume":"96","author":"Song","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"2026012101525801600_dgaf540-B52","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00701-016-2762-z","article-title":"Reasons and results of endoscopic surgery for prolactinomas: 142 surgical cases","volume":"158","author":"Akin","year":"2016","journal-title":"Acta Neurochir (Wien)"},{"issue":"4","key":"2026012101525801600_dgaf540-B53","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1159\/000358673","article-title":"GAL3 protein expression is related to clinical features of prolactin-secreting pituitary microadenoma and predicts its recurrence after surgical treatment","volume":"33","author":"Dai","year":"2014","journal-title":"Cell Physiol Biochem"},{"issue":"13","key":"2026012101525801600_dgaf540-B54","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.3390\/jcm11133920","article-title":"Extra-pseudocapsular transsphenoidal surgery for microprolactinoma in women","volume":"11","author":"Chen","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"2026012101525801600_dgaf540-B55","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12902-023-01343-0","article-title":"Operative treatment of cystic prolactinomas: a retrospective study","volume":"23","author":"Su","year":"2023","journal-title":"BMC Endocr Disord"},{"issue":"4","key":"2026012101525801600_dgaf540-B56","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s42000-021-00309-y","article-title":"Outcomes of transsphenoidal surgery in dopamine agonist-resistant prolactinomas: a retrospective study","volume":"20","author":"Wei","year":"2021","journal-title":"Hormones (Athens)"},{"key":"2026012101525801600_dgaf540-B57","doi-asserted-by":"crossref","first-page":"e858","DOI":"10.1016\/j.wneu.2022.12.003","article-title":"Endoscopic transnasal approach for microprolactinomas with experience of 105 cases in a single center: paradigmal shift for conventional medical therapy","volume":"170","author":"Uzuner","year":"2023","journal-title":"World Neurosurg"},{"issue":"6","key":"2026012101525801600_dgaf540-B58","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1530\/EJE-21-0293","article-title":"Pituitary surgery as alternative to dopamine agonists treatment for microprolactinomas: a cohort study","volume":"185","author":"Baussart","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"2026012101525801600_dgaf540-B59","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3389\/fendo.2020.00439","article-title":"Prolactinomas: prognostic factors of early remission after transsphenoidal surgery","volume":"11","author":"Zielinski","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"2026012101525801600_dgaf540-B60","first-page":"1006","article-title":"Pure endoscopic endonasal approach for pituitary adenomas: early surgical results in 200 patients and comparison with previous microsurgical series","volume":"62","author":"Dehdashti","year":"2008","journal-title":"Neurosurgery"},{"key":"2026012101525801600_dgaf540-B61"},{"issue":"(1)","key":"2026012101525801600_dgaf540-B62","first-page":"e9","article-title":"Subtle cognitive impairments and psychological complaints in patients with prolactinoma despite biochemical control","volume":"111","author":"van Trigt","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026012101525801600_dgaf540-B63","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s11102-017-0860-4","article-title":"How non-functioning pituitary adenomas can affect health-related quality of life: a conceptual model and literature review","volume":"21","author":"Andela","year":"2018","journal-title":"Pituitary"},{"key":"2026012101525801600_dgaf540-B64","doi-asserted-by":"crossref","first-page":"e686","DOI":"10.1016\/j.wneu.2019.05.249","article-title":"Radiographic and hormonal regression in prolactinomas: an analysis of treatment failure","volume":"129","author":"Akinduro","year":"2019","journal-title":"World Neurosurg"},{"issue":"4","key":"2026012101525801600_dgaf540-B65","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1210\/jcem-60-4-698","article-title":"Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study","volume":"60","author":"Molitch","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026012101525801600_dgaf540-B66","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1210\/jcem-68-2-412","article-title":"The natural history of untreated hyperprolactinemia: a prospective analysis","volume":"68","author":"Schlechte","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026012101525801600_dgaf540-B67","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/BF03343561","article-title":"Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline","volume":"22","author":"Cannav\u00f2","year":"1999","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2026012101525801600_dgaf540-B68","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1023\/A:1026225625897","article-title":"Dopamine resistance of prolactinomas","volume":"6","author":"Molitch","year":"2003","journal-title":"Pituitary"},{"issue":"4","key":"2026012101525801600_dgaf540-B69","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11102-016-0723-4","article-title":"Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas","volume":"19","author":"Shimon","year":"2016","journal-title":"Pituitary"},{"issue":"1","key":"2026012101525801600_dgaf540-B70","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12020-022-03145-1","article-title":"Cardiometabolic profile of young women with hypoprolactinemia","volume":"78","author":"Krysiak","year":"2022","journal-title":"Endocrine"},{"issue":"1","key":"2026012101525801600_dgaf540-B71","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/jsm.12327","article-title":"Low prolactin is associated with sexual dysfunction and psychological or metabolic disturbances in middle-aged and elderly men: the European Male Aging Study (EMAS)","volume":"11","author":"Corona","year":"2014","journal-title":"J Sex Med"},{"issue":"4","key":"2026012101525801600_dgaf540-B72","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/cen.14283","article-title":"Sexual function and depressive symptoms in young women with hypoprolactinaemia","volume":"93","author":"Krysiak","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"2026012101525801600_dgaf540-B73","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1007\/s40618-023-02101-8","article-title":"Low prolactin level identifies hypoactive sexual desire disorder women with a reduced inhibition profile","volume":"46","author":"Maseroli","year":"2023","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"2026012101525801600_dgaf540-B74","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3171\/jns.2002.97.2.0307","article-title":"Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery","volume":"97","author":"Amar","year":"2002","journal-title":"J Neurosurg"},{"issue":"2","key":"2026012101525801600_dgaf540-B75","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11102-013-0473-5","article-title":"Is a stable or decreasing prolactin level in a patient with prolactinoma a surrogate marker for lack of tumor growth?","volume":"17","author":"Alkabbani","year":"2014","journal-title":"Pituitary"},{"issue":"3","key":"2026012101525801600_dgaf540-B76","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1227\/00006123-198903000-00020","article-title":"Growth of prolactinoma despite lowering of serum prolactin by bromocriptine","volume":"24","author":"Kupersmith","year":"1989","journal-title":"Neurosurgery"},{"issue":"1","key":"2026012101525801600_dgaf540-B77","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF03350560","article-title":"Reenlargement of macroprolactinomas during bromocriptine treatment: report of two cases","volume":"6","author":"Dallabonzana","year":"1983","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2026012101525801600_dgaf540-B78","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11102-019-01001-6","article-title":"Magnetic resonance imaging in\u202fthe management of prolactinomas; a review of the evidence","volume":"23","author":"Varlamov","year":"2020","journal-title":"Pituitary"},{"issue":"7","key":"2026012101525801600_dgaf540-B79","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1210\/jc.2008-2103","article-title":"Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy","volume":"94","author":"Kharlip","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026012101525801600_dgaf540-B80","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s11102-017-0806-x","article-title":"Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal","volume":"20","author":"Teixeira","year":"2017","journal-title":"Pituitary"},{"issue":"1","key":"2026012101525801600_dgaf540-B81","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s12020-016-1115-2","article-title":"10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas","volume":"55","author":"Andereggen","year":"2017","journal-title":"Endocrine"},{"issue":"2","key":"2026012101525801600_dgaf540-B82","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s12020-018-1702-5","article-title":"Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas","volume":"62","author":"Huang","year":"2018","journal-title":"Endocrine"},{"issue":"1","key":"2026012101525801600_dgaf540-B83","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s12020-020-02388-0","article-title":"High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?","volume":"70","author":"Espinosa-C\u00e1rdenas","year":"2020","journal-title":"Endocrine"},{"issue":"8","key":"2026012101525801600_dgaf540-B84","doi-asserted-by":"crossref","first-page":"e3069","DOI":"10.1210\/clinem\/dgab159","article-title":"Radiomics with ensemble machine learning predicts dopamine agonist response in patients with prolactinoma","volume":"106","author":"Park","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026012101525801600_dgaf540-B85","doi-asserted-by":"crossref","first-page":"e3300","DOI":"10.1210\/clinem\/dgab138","article-title":"Outcome squares integrating efficacy and safety, as applied to functioning pituitary adenoma surgery","volume":"106","author":"de Vries","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026012101525801600_dgaf540-B86","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11102-024-01392-1","article-title":"Quality of life in prolactinoma: a systematic review","volume":"27","author":"Castle-Kirszbaum","year":"2024","journal-title":"Pituitary"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf540\/64425189\/dgaf540.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/2\/303\/64425189\/dgaf540.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/2\/303\/64425189\/dgaf540.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T06:53:33Z","timestamp":1768978413000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/2\/303\/8267660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":86,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,9,29]]},"published-print":{"date-parts":[[2026,1,21]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf540","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,9,29]]}}}